Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ASPI 
ASP Isotopes Inc. Common Stock (ASPI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/13/2026: ASPI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Upturn Star Rating
Analysis of Past Performance
Type Stock | Historic Profit 170.13% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 02/13/2026 |
Company Fundamentals
Each bar represents the company's percentile performance relative to peers (0–100%).
Measures profit generation across gross margin, operating margin, net margin, and EBITDA margin.
Financial Health Rating
Each bar represents the company's percentile performance relative to peers (0–100%).
Measures profit generation across gross margin, operating margin, net margin, and EBITDA margin.
Growth Momentum Score
Each bar represents the company's percentile strength (0–10 scale).
Revenue Growth: Measures how fast the company's revenue is growing compared to last year.
Ownership
Each bar represents the company's percentile strength (0–10 scale).
Unit Economics
Each bar represents the company's percentile strength (0–10 scale).
Quantitative Style
Each bar represents the company's percentile strength (0–10 scale).
Competitive Positioning
Each bar represents the company's percentile strength (0–10 scale).
Financial Metrics Analysis
Institutional Ownership
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 653.07M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 3.49 | 52 Weeks Range 3.65 - 14.49 | Updated Date 02/14/2026 |
52 Weeks Range 3.65 - 14.49 | Updated Date 02/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -306.1% |
Management Effectiveness
Return on Assets (TTM) -17.15% | Return on Equity (TTM) -152.56% |
Valuation
Trailing PE - | Forward PE 54.35 | Enterprise Value 652163693 | Price to Sales(TTM) 77.9 |
Enterprise Value 652163693 | Price to Sales(TTM) 77.9 | ||
Enterprise Value to Revenue 77.79 | Enterprise Value to EBITDA -12.17 | Shares Outstanding 125110122 | Shares Floating 88076886 |
Shares Outstanding 125110122 | Shares Floating 88076886 | ||
Percent Insiders 17.28 | Percent Institutions 55.81 |
About ASP Isotopes Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2022-11-10 | Executive Chairman & CEO Mr. Paul Elliot Mann C.F.A. | ||
Sector Basic Materials | Industry Chemicals | Full time employees 136 | Website https://aspisotopes.com |
Full time employees 136 | Website https://aspisotopes.com | ||
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-67/68, Nickel-64, and Xenon 129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. ASP Isotopes Inc. was incorporated in 2021 and is based in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.